S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
Best Bear Market Funds: Top 3 Investment Options to Consider
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
Best Bear Market Funds: Top 3 Investment Options to Consider
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
Best Bear Market Funds: Top 3 Investment Options to Consider
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
Best Bear Market Funds: Top 3 Investment Options to Consider
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal

Madrigal Pharmaceuticals (MDGL) Stock Price, News & Analysis

$258.81
+11.19 (+4.52%)
(As of 03/27/2024 ET)
Today's Range
$244.85
$259.53
50-Day Range
$171.37
$283.23
52-Week Range
$119.76
$322.67
Volume
442,701 shs
Average Volume
727,283 shs
Market Capitalization
$5.15 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$377.40

Madrigal Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.90 Rating Score
Upside/​Downside
45.8% Upside
$377.40 Price Target
Short Interest
Healthy
20.17% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.92
Upright™ Environmental Score
News Sentiment
0.62mentions of Madrigal Pharmaceuticals in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($21.48) to ($13.50) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.88 out of 5 stars

Medical Sector

37th out of 939 stocks

Pharmaceutical Preparations Industry

15th out of 429 stocks

MDGL stock logo

About Madrigal Pharmaceuticals Stock (NASDAQ:MDGL)

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

MDGL Stock Price History

MDGL Stock News Headlines

7 Stocks That Will Drive the Weight Loss Drugs Market (MDGL)
The booming weight loss drug market presents both lucrative potential and significant risks for investors seeking to capitalize on the global obesity crisis.
$25,000 into $109,616 in two months?
Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…
MDGL May 2024 390.000 call
MDGL May 2024 350.000 call
The AI Defense Stock Set to Soar
To protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.
MDGL May 2024 230.000 put
MDGL Jun 2024 410.000 put
MDGL May 2024 260.000 put
Madrigal Pharmaceuticals (NASDAQ:MDGL) PT Raised to $389.00
7 Biotech Stocks Ready to Ride the Sector's Resurgence
See More Headlines
Receive MDGL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Madrigal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
3/28/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:MDGL
CUSIP
87162T20
Employees
376
Year Founded
2011

Price Target and Rating

Average Stock Price Target
$377.40
High Stock Price Target
$425.00
Low Stock Price Target
$270.00
Potential Upside/Downside
+45.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.90
Research Coverage
10 Analysts

Profitability

Net Income
$-373,630,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$20.53 per share

Miscellaneous

Free Float
15,138,000
Market Cap
$5.15 billion
Optionable
Optionable
Beta
-0.48

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Dr. Rebecca A. Taub M.D. (Age 72)
    Founder, Chief Medical Officer, President of Research & Development and Director
    Comp: $939.83k
  • Mr. Alex G. Howarth (Age 54)
    Senior VP & CFO
    Comp: $757.26k
  • Mr. Brian J. Lynch J.D. (Age 62)
    Senior VP & General Counsel
    Comp: $763.75k
  • Mr. William J. Sibold (Age 58)
    CEO, President & Director
  • Mr. Ronald Filippo
    Chief Information Officer
  • Ms. Tina E. Ventura
    Chief Investor Relations Officer
  • Dr. Kianoush Motesharei Ph.d. (Age 54)
    Senior Vice President of Business & Corporate Development
  • Mr. Clint Wallace
    Chief Human Resources Officer
  • Mr. Edward Chiang
    Senior Vice President of Clinical & Technical Operations
  • Mr. Thomas W. Hare
    Senior Vice President of Clinical Management

MDGL Stock Analysis - Frequently Asked Questions

Should I buy or sell Madrigal Pharmaceuticals stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Madrigal Pharmaceuticals in the last year. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MDGL shares.
View MDGL analyst ratings
or view top-rated stocks.

What is Madrigal Pharmaceuticals' stock price target for 2024?

10 analysts have issued twelve-month price objectives for Madrigal Pharmaceuticals' shares. Their MDGL share price targets range from $270.00 to $425.00. On average, they expect the company's stock price to reach $377.40 in the next twelve months. This suggests a possible upside of 45.8% from the stock's current price.
View analysts price targets for MDGL
or view top-rated stocks among Wall Street analysts.

How have MDGL shares performed in 2024?

Madrigal Pharmaceuticals' stock was trading at $231.38 at the beginning of the year. Since then, MDGL shares have increased by 11.9% and is now trading at $258.81.
View the best growth stocks for 2024 here
.

When is Madrigal Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our MDGL earnings forecast
.

How were Madrigal Pharmaceuticals' earnings last quarter?

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) released its earnings results on Wednesday, February, 28th. The biopharmaceutical company reported ($5.68) earnings per share for the quarter, missing the consensus estimate of ($5.26) by $0.42. During the same period last year, the firm earned ($4.98) earnings per share.

What ETFs hold Madrigal Pharmaceuticals' stock?
What other stocks do shareholders of Madrigal Pharmaceuticals own?
Who are Madrigal Pharmaceuticals' major shareholders?

Madrigal Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Avoro Capital Advisors LLC (9.57%), Vanguard Group Inc. (7.98%), Vanguard Group Inc. (7.91%), Paulson & CO. Inc. (5.60%), RTW Investments LP (4.13%) and Price T Rowe Associates Inc. MD (1.97%). Insiders that own company stock include Brian Joseph Lynch, Bros Advisors Lp Baker, Remy Sukhija, Richard S Levy and Robert E Waltermire.
View institutional ownership trends
.

How do I buy shares of Madrigal Pharmaceuticals?

Shares of MDGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MDGL) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners